NUWIQ (simoctocog alfa), human coagulation factor (factor VIII)
HAEMATOLOGY - New medicinal product
Opinions on drugs -
Posted on
Jan 05 2016
Reason for request
Inclusion
No clinical benefit demonstrated by comparison with other coagulation factor VIII products in the treatment and prophylaxis of bleeding in patients with haemophilia A.
- NUWIQ has Marketing Authorisation in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). This factor VIII is produced in host cells of human origin (human embryonic kidney (HEK) 293 F cells).
- In phase III trials with this product no patients developed anti-factor VIII inhibitors, which is a major complication of factor VIII replacement therapy.
- The safety profile appears to be similar in children and adults.
Clinical Benefit
Substantial |
- |
Clinical Added Value
no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments